Our study sought to describe ocular surface alterations at baseline and after 4 months of dupilumab treatment in patients with severe AD. Our findings highlight that all 25 patients showed ocular surface alterations prior to dupilumab treatment. Dupilumab may cause the worsening of clinical or subclinical pre-existing ocular alterations belonging to the spectrum of AKC.
New insights on ocular surface disease in patients with atopic dermatitis treated with dupilumab / P. Bortoluzzi, S. Ferrucci, D. Galimberti, F. Garavelli, F. Pozzo Giuffrida, A. Pizzati, A.V. Marzano, C. Mapelli. - In: BRITISH JOURNAL OF DERMATOLOGY. - ISSN 1365-2133. - (2021), pp. 1-3. [Epub ahead of print] [10.1111/bjd.20706]
New insights on ocular surface disease in patients with atopic dermatitis treated with dupilumab
P. Bortoluzzi
Primo
;D. Galimberti;F. Garavelli;F. Pozzo Giuffrida;A. Pizzati;A.V. MarzanoPenultimo
;C. Mapelli
2021
Abstract
Our study sought to describe ocular surface alterations at baseline and after 4 months of dupilumab treatment in patients with severe AD. Our findings highlight that all 25 patients showed ocular surface alterations prior to dupilumab treatment. Dupilumab may cause the worsening of clinical or subclinical pre-existing ocular alterations belonging to the spectrum of AKC.File | Dimensione | Formato | |
---|---|---|---|
bjd.20706.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
1.08 MB
Formato
Adobe PDF
|
1.08 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.